WO2009041565A1 - キナゾリノン誘導体又はキノキサリン誘導体を有効成分として含む角結膜障害の予防又は治療剤 - Google Patents

キナゾリノン誘導体又はキノキサリン誘導体を有効成分として含む角結膜障害の予防又は治療剤 Download PDF

Info

Publication number
WO2009041565A1
WO2009041565A1 PCT/JP2008/067404 JP2008067404W WO2009041565A1 WO 2009041565 A1 WO2009041565 A1 WO 2009041565A1 JP 2008067404 W JP2008067404 W JP 2008067404W WO 2009041565 A1 WO2009041565 A1 WO 2009041565A1
Authority
WO
WIPO (PCT)
Prior art keywords
corneal
prophylactic
quinazolinone derivative
therapeutic agent
atom
Prior art date
Application number
PCT/JP2008/067404
Other languages
English (en)
French (fr)
Inventor
Sayo Habashita
Shin-Ichiro Hirai
Original Assignee
Santen Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co., Ltd. filed Critical Santen Pharmaceutical Co., Ltd.
Publication of WO2009041565A1 publication Critical patent/WO2009041565A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

　一般式(I)で表される化合物又はその塩は、ＳＡＭＰ１０を用いた薬理試験において、加齢に伴って発症する角膜障害等に対して優れた予防及び改善効果を発揮するので、ドライアイ、点状表層角膜症、角膜上皮欠損などの角結膜障害の予防又は治療剤として有用である。一般式(I)の式中、Ａ１－Ａ２は基１を示し、Ｘは基２等を示し、Ｙは炭素原子又は窒素原子を示し、破線は単結合又は二重結合を示し、Ｌは単結合、アルキレン基、シクロアルケニレン基等を示し、Ｒ１ａとＲ１ｂは同一又は異なって水素原子、ハロゲン原子等を示し、Ｒ２は水素原子又はハロゲン原子を示し、Ｒ３は水素原子又はハロゲン原子を示す。 【化１】
PCT/JP2008/067404 2007-09-26 2008-09-26 キナゾリノン誘導体又はキノキサリン誘導体を有効成分として含む角結膜障害の予防又は治療剤 WO2009041565A1 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-249359 2007-09-26
JP2007249359 2007-09-26

Publications (1)

Publication Number Publication Date
WO2009041565A1 true WO2009041565A1 (ja) 2009-04-02

Family

ID=40511445

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/067404 WO2009041565A1 (ja) 2007-09-26 2008-09-26 キナゾリノン誘導体又はキノキサリン誘導体を有効成分として含む角結膜障害の予防又は治療剤

Country Status (2)

Country Link
JP (1) JP2009096804A (ja)
WO (1) WO2009041565A1 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013008872A1 (ja) 2011-07-13 2013-01-17 参天製薬株式会社 Ｐａｒｐ阻害活性を有する新規化合物
US9359367B2 (en) 2012-07-09 2016-06-07 Lupin Limited Tetrahydroquinazolinone derivatives as PARP inhibitors

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2752150A1 (en) * 2009-02-11 2010-08-19 Reaction Biology Corp. Selective kinase inhibitors
US10045981B2 (en) 2015-11-24 2018-08-14 Jakpharm, Llc Selective kinase inhibitors
KR102030016B1 (ko) * 2016-09-05 2019-10-08 충남대학교산학협력단 신규한 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 폴리(adp-리보스)폴리머라제-1(parp-1) 관련 질환의 예방 또는 치료용 약학적 조성물
JP7429500B2 (ja) * 2018-03-02 2024-02-08 公立大学法人和歌山県立医科大学 角膜上皮障害治療剤

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000077197A1 (en) * 1999-06-11 2000-12-21 Human Genome Sciences, Inc. 47 human secreted proteins
WO2002048711A1 (fr) * 2000-12-11 2002-06-20 Iatron Laboratories, Inc. Reactifs d'analyse immunologique et procede d'analyse
WO2003007959A1 (en) * 2001-07-16 2003-01-30 Fujisawa Pharmaceutical Co., Ltd. Quinoxaline derivatives which have parp inhibitory action
WO2003055865A1 (en) * 2001-12-24 2003-07-10 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
WO2003063874A1 (en) * 2002-01-29 2003-08-07 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
WO2003080581A1 (en) * 2002-03-26 2003-10-02 Fujisawa Pharmaceutical Co., Ltd. Phenanthridinones as parp inhibitors
WO2005009398A2 (en) * 2003-02-28 2005-02-03 Inotek Pharmaceuticals Corporation Tetracyclic benzamide derivatives and methods of use thereof
WO2005082079A2 (en) * 2004-02-26 2005-09-09 Inotek Pharmaceuticals Corporation Tetracyclic lactam derivatives and uses thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000077197A1 (en) * 1999-06-11 2000-12-21 Human Genome Sciences, Inc. 47 human secreted proteins
WO2002048711A1 (fr) * 2000-12-11 2002-06-20 Iatron Laboratories, Inc. Reactifs d'analyse immunologique et procede d'analyse
WO2003007959A1 (en) * 2001-07-16 2003-01-30 Fujisawa Pharmaceutical Co., Ltd. Quinoxaline derivatives which have parp inhibitory action
WO2003055865A1 (en) * 2001-12-24 2003-07-10 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
WO2003063874A1 (en) * 2002-01-29 2003-08-07 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
WO2003080581A1 (en) * 2002-03-26 2003-10-02 Fujisawa Pharmaceutical Co., Ltd. Phenanthridinones as parp inhibitors
WO2005009398A2 (en) * 2003-02-28 2005-02-03 Inotek Pharmaceuticals Corporation Tetracyclic benzamide derivatives and methods of use thereof
WO2005082079A2 (en) * 2004-02-26 2005-09-09 Inotek Pharmaceuticals Corporation Tetracyclic lactam derivatives and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DELL,S. ET AL.: "The Role of PDGF Receptor Inhibitors and PI3-Kinase Signaling in the Pathogenesis of Corneal Neovascularization", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 47, no. 5, 2006, pages 1928 - 37 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013008872A1 (ja) 2011-07-13 2013-01-17 参天製薬株式会社 Ｐａｒｐ阻害活性を有する新規化合物
US9062061B2 (en) 2011-07-13 2015-06-23 Santen Pharmaceutical Co., Ltd. Compound having PARP inhibitory activity
US9359367B2 (en) 2012-07-09 2016-06-07 Lupin Limited Tetrahydroquinazolinone derivatives as PARP inhibitors

Also Published As

Publication number Publication date
JP2009096804A (ja) 2009-05-07

Similar Documents

Publication Publication Date Title
WO2009041565A1 (ja) キナゾリノン誘導体又はキノキサリン誘導体を有効成分として含む角結膜障害の予防又は治療剤
EP1864665A4 (en) IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING A HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT
WO2008087933A1 (ja) ＩκＢキナーゼβ阻害活性を有する新規インドール誘導体
WO2006100635A3 (en) Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists
NO20054208L (no) Nitrogen-substituerte heksahydropyrazino[1,2-a]pyrimidin-4,7-dionderivater, fremgangsmater for fremstilling og anvendelse derav som medikamenter
TW200740805A (en) Novel compounds
WO2007136116A3 (en) C-phenyl glycitol compound for the treatment of diabetes
WO2008006043A3 (en) 1,3-oxazole derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents
EP1854789A4 (en) CHINAZOLINE DERIVATIVE WITH TYROSINE KINASE HEMMENDER EFFECT
NZ592533A (en) METHOD FOR THE PREPARATION OF N-(5-CHLORO-2-PYRIDINYL)-2-[[4-[(DIMETHYLAMINO) IMINOMETHYL] BENZOYL] AMINO]-5-METHOXY-BENZAMIDE, A FACTOR Xa INHIBITOR
WO2007048064A3 (en) Amino-pyrimidines as casein kinase ii (ck2) modulators
TW200606152A (en) Piperidine compound and process for preparing the same
MXPA04001685A (es) Derivados de sulfonilamino empleados como herbicida.
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
NO20063230L (no) CRF receptorantagonister og fremgangsmater for fremstilling derav
NO20033145D0 (no) Purinderivater som purinergiske reseptorantagonister
WO2007098030A8 (en) Selective n-sulfonylation of 2-amino trifluoroalkyl substituted alcohols
WO2007053495A3 (en) Compounds useful as antagonists of ccr2
WO2009156864A3 (en) Substituted alkyl pyrimidin-4-one derivatives
WO2008136444A1 (ja) 縮合複素環誘導体
EA200901402A1 (ru) Терапевтическое средство против глаукомы, содержащее в качестве активного ингредиента производное аденозина
TW200730527A (en) Fused heterocyclic compound
WO2007068728A3 (en) N-substituted pyrrolopyridinones active as kinase inhibitors
WO2009114325A3 (en) Methotrexate adjuvants to reduce toxicity and methods for using the same
WO2008149834A1 (ja) ピリミドジアゼピノン誘導体

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08832902

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08832902

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP